Literature DB >> 10440972

Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample.

C A Luis1, W W Barker, K Gajaraj, D Harwood, R Petersen, A Kashuba, C Waters, P Jimison, G Pearl, C Petito, D Dickson, R Duara.   

Abstract

OBJECTIVE: To evaluate the sensitivity and specificity of the clinical features of three published diagnostic criteria for diffuse Lewy body disease (DLBD) using autopsy-confirmed Alzheimer's (AD), DLBD and AD+DLBD (mixed) dementia cases.
DESIGN: Retrospective chart review of an autopsy series of 56 patients selected from the State of Florida Brain Bank on the basis of a pathological diagnosis of either pure AD, DLBD (pure and common forms) or AD+DLBD (mixed) dementia. Clinical features were assessed by three raters blind to the pathological diagnosis.
RESULTS: The existing criteria for a clinical diagnosis of DLBD were highly specific (90-100%) but not very sensitive (49-63%) in the differential diagnosis of DLBD versus AD; sensitivity did improve (61-74%) when mixed AD+DLBD cases were eliminated. Clinical features that occur more frequently in DLBD than in AD were unspecified hallucinations, unspecified EPS, fluctuating course and rapid progression. Post-hoc analysis also indicated that hallucinations and EPS were more common early in the disease course of DLBD than in AD. Empirically derived criteria, formulated using the most prevalent clinical features, demonstrated sensitivity values of 57-96% for pure forms and 43-91% for mixed forms.
CONCLUSIONS: This study demonstrated that additional improvements in the established criteria for DLBD are needed. Our empirically derived criteria enhanced the distinction of DLBD from AD while allowing the clinician the choice of maximizing sensitivity with acceptable specificity, and vice versa. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10440972

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  20 in total

1.  Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease.

Authors:  T A Ala; L F Hughes; G A Kyrouac; M W Ghobrial; R J Elble
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

2.  Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders.

Authors:  Thomas G Beach; Charles H Adler; Geidy Serrano; Lucia I Sue; D G Walker; Brittany N Dugger; Holly A Shill; Erika Driver-Dunckley; John N Caviness; Anthony Intorcia; Jessica Filon; Sarah Scott; Angelica Garcia; Brittany Hoffman; Christine M Belden; Kathryn J Davis; Marwan N Sabbagh
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

3.  From the heart to the brain via cardiac MIBG imaging.

Authors:  Montserrat Estorch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03       Impact factor: 9.236

4.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

5.  Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases.

Authors:  Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

Review 6.  Diffuse Lewy body disease: clinical, pathological, and neuropsychological review.

Authors:  C A Luis; W Mittenberg; C S Gass; R Duara
Journal:  Neuropsychol Rev       Date:  1999-09       Impact factor: 7.444

Review 7.  Dementia with Lewy bodies. Review of diagnosis and pharmacologic management.

Authors:  Christopher Frank
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

8.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.

Authors:  Z Walker; D C Costa; R W H Walker; K Shaw; S Gacinovic; T Stevens; G Livingston; P Ince; I G McKeith; C L E Katona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

9.  Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype.

Authors:  James B Leverenz; Mark A Fishel; Elaine R Peskind; Thomas J Montine; David Nochlin; Ellen Steinbart; Murray A Raskind; Gerard D Schellenberg; Thomas D Bird; Debby Tsuang
Journal:  Arch Neurol       Date:  2006-03

Review 10.  Benefit-risk considerations in the treatment of dementia with Lewy bodies.

Authors:  Margaret M Swanberg; Jeffrey L Cummings
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.